ARCHIVES

Dasatinib, Nilotinib Show Strong Early Results As Frontline Therapy For CML

This article is from The Cancer Letter archive.

Vol. 30 No. 12 | December 28, 2007

Download PDF Visit The Full Archive

Related Articles

Congressional Committee, SEC Probe ImClone’s Statements To Shareholders.

January 25, 2002

Chabner Criticizes FDA Crackdown On Off-Label Info

June 28, 1991

ACOS Planning Patient Care Melanoma Study

August 4, 1989

Montefore Oncology Dept. Writes In Support of Peter Wiernik

November 12, 1993

National Cancer Institute Lists Approved Clinical Trials

January 31, 2003

Children’s Oncology Group to Select New Chairman; Four Leaders to Step Aside

April 28, 2000